Lanreotide (30 mg/week by intramuscular injection) in 30 patients with prostate cancer refractory to metastatic hormones with an average duration of 12 weeks (2–60 weeks) improved functional status (40%) and bone pain (35%), decreased >50% in prostate-specific antigen (PSA) levels, and stabilized PSA levels in 20% and 16% of patients, respectively. This evidence concerns the gene KLK3 and prostate carcinoma.